Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Biotech & Life Sciences

Johnson & Johnson’s ICOTYDE brings a new oral IL-23 option to plaque psoriasis

Johnson & Johnson
Table of Contents

On March 17, 2026, the FDA approved Johnson & Johnson’s ICOTYDE (icotrokinra) for adults and pediatric patients 12 years and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

ICOTYDE is a once-daily oral IL-23 receptor antagonist, and Johnson & Johnson describes it as the first and only targeted oral peptide approved for this indication. Johnson & Johnson said that, in head-to-head superiority studies, approximately 55% of ICOTYDE-treated patients achieved PASI 90 at Week 16.

The most common adverse reactions were headache, nausea, cough, fungal infection, and tiredness. Johnson & Johnson also says icotrokinra is being studied in active psoriatic arthritis, moderately-to-severely active ulcerative colitis, and moderately-to-severely active Crohn’s disease.

Sources: FDA Novel Drugs for 2026, Johnson & Johnson Press Release, ICOTYDE

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments